These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31765060)

  • 1. Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure.
    Rodríguez Cruz PM; Cossins J; Cheung J; Maxwell S; Jayawant S; Herbst R; Waithe D; Kornev AP; Palace J; Beeson D
    Hum Mutat; 2020 Mar; 41(3):619-631. PubMed ID: 31765060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in MUSK causing congenital myasthenic syndrome impair MuSK-Dok-7 interaction.
    Maselli RA; Arredondo J; Cagney O; Ng JJ; Anderson JA; Williams C; Gerke BJ; Soliven B; Wollmann RL
    Hum Mol Genet; 2010 Jun; 19(12):2370-9. PubMed ID: 20371544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUSK, a new target for mutations causing congenital myasthenic syndrome.
    Chevessier F; Faraut B; Ravel-Chapuis A; Richard P; Gaudon K; Bauché S; Prioleau C; Herbst R; Goillot E; Ioos C; Azulay JP; Attarian S; Leroy JP; Fournier E; Legay C; Schaeffer L; Koenig J; Fardeau M; Eymard B; Pouget J; Hantaï D
    Hum Mol Genet; 2004 Dec; 13(24):3229-40. PubMed ID: 15496425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathophysiological characterization of congenital myasthenic syndromes: the example of mutations in the MUSK gene].
    Chevessier F; Faraut B; Ravel-Chapuis A; Richard P; Gaudon K; Bauché S; Prioleau C; Herbst R; Goillot E; Ioos C; Azulay JP; Attarian S; Leroy JP; Fournier E; Legay C; Schaeffer L; Koenig J; Fardeau M; Eymard B; Pouget J; Hantaï D
    J Soc Biol; 2005; 199(1):61-77. PubMed ID: 16114265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.
    Ohkawara B; Cabrera-Serrano M; Nakata T; Milone M; Asai N; Ito K; Ito M; Masuda A; Ito Y; Engel AG; Ohno K
    Hum Mol Genet; 2014 Apr; 23(7):1856-68. PubMed ID: 24234652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dok-7/MuSK signaling and a congenital myasthenic syndrome.
    Yamanashi Y; Higuch O; Beeson D
    Acta Myol; 2008 Jul; 27(1):25-9. PubMed ID: 19108574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK.
    Gallenmüller C; Müller-Felber W; Dusl M; Stucka R; Guergueltcheva V; Blaschek A; von der Hagen M; Huebner A; Müller JS; Lochmüller H; Abicht A
    Neuromuscul Disord; 2014 Jan; 24(1):31-5. PubMed ID: 24183479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synaptic muscle-specific kinase (MuSK) complex: new partners, new functions.
    Strochlic L; Cartaud A; Cartaud J
    Bioessays; 2005 Nov; 27(11):1129-35. PubMed ID: 16237673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mutation causes MuSK reduced sensitivity to agrin and congenital myasthenia.
    Ben Ammar A; Soltanzadeh P; Bauché S; Richard P; Goillot E; Herbst R; Gaudon K; Huzé C; Schaeffer L; Yamanashi Y; Higuchi O; Taly A; Koenig J; Leroy JP; Hentati F; Najmabadi H; Kahrizi K; Ilkhani M; Fardeau M; Eymard B; Hantaï D
    PLoS One; 2013; 8(1):e53826. PubMed ID: 23326516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders.
    Clausen L; Cossins J; Beeson D
    J Neuromuscul Dis; 2018; 5(2):231-240. PubMed ID: 29865088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mouse model for congenital myasthenic syndrome due to MuSK mutations reveals defects in structure and function of neuromuscular junctions.
    Chevessier F; Girard E; Molgó J; Bartling S; Koenig J; Hantaï D; Witzemann V
    Hum Mol Genet; 2008 Nov; 17(22):3577-95. PubMed ID: 18718936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia.
    Oury J; Zhang W; Leloup N; Koide A; Corrado AD; Ketavarapu G; Hattori T; Koide S; Burden SJ
    Nature; 2021 Jul; 595(7867):404-408. PubMed ID: 34163073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance.
    Messéant J; Dobbertin A; Girard E; Delers P; Manuel M; Mangione F; Schmitt A; Le Denmat D; Molgó J; Zytnicki D; Schaeffer L; Legay C; Strochlic L
    J Neurosci; 2015 Mar; 35(12):4926-41. PubMed ID: 25810523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved plasma membrane expression of the trafficking defective P344R mutant of muscle, skeletal, receptor tyrosine kinase (MuSK) causing congenital myasthenic syndrome.
    Milhem RM; Al-Gazali L; Ali BR
    Int J Biochem Cell Biol; 2015 Mar; 60():119-29. PubMed ID: 25562515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.
    Maselli RA; Fernandez JM; Arredondo J; Navarro C; Ngo M; Beeson D; Cagney O; Williams DC; Wollmann RL; Yarov-Yarovoy V; Ferns MJ
    Hum Genet; 2012 Jul; 131(7):1123-35. PubMed ID: 22205389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and activation of MuSK, a receptor tyrosine kinase central to neuromuscular junction formation.
    Hubbard SR; Gnanasambandan K
    Biochim Biophys Acta; 2013 Oct; 1834(10):2166-9. PubMed ID: 23467009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of MuSK in synapse formation and neuromuscular disease.
    Burden SJ; Yumoto N; Zhang W
    Cold Spring Harb Perspect Biol; 2013 May; 5(5):a009167. PubMed ID: 23637281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization.
    Bergamin E; Hallock PT; Burden SJ; Hubbard SR
    Mol Cell; 2010 Jul; 39(1):100-9. PubMed ID: 20603078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mutation in DOK7 in congenital myasthenic syndrome forms aggresome in cultured cells, and reduces DOK7 expression and MuSK phosphorylation in patient-derived iPS cells.
    Zhang S; Ohkawara B; Ito M; Huang Z; Zhao F; Nakata T; Takeuchi T; Sakurai H; Komaki H; Kamon M; Araki T; Ohno K
    Hum Mol Genet; 2023 Apr; 32(9):1511-1523. PubMed ID: 36579833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations causing DOK7 congenital myasthenia ablate functional motifs in Dok-7.
    Hamuro J; Higuchi O; Okada K; Ueno M; Iemura S; Natsume T; Spearman H; Beeson D; Yamanashi Y
    J Biol Chem; 2008 Feb; 283(9):5518-24. PubMed ID: 18165682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.